Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction

Giovanni Melandri
Fabio Vagnarelli
Daniela Calabrese
Franco Semprini
Samuele Nanni
Angelo Branzi
Dipartimento Cardiovascolare, Università di Bologna, Italy

Abstract: TNKase is a genetically engineered variant of the alteplase molecule. Three different mutations result in an increase of the plasma half-life, of the resistance to plasminogen-activator inhibitor 1 and of the thrombolytic potency against platelet-rich thrombi. Among available agents in clinical practice, TNKase is the most fibrin-specific molecule and can be delivered as a single bolus intravenous injection. Several large-scale clinical trials have enrolled more than 27,000 patients with acute myocardial infarction, making the use of this drug truly evidence-based. TNKase is equivalent to front-loaded alteplase in terms of mortality and is the only bolus thrombolytic drug for which this equivalence has been formally demonstrated. TNKase appears more potent than alteplase when symptoms duration lasts more than 4 hours. Also, TNKase significantly reduces the rate of major bleeds and the need for blood transfusions. The efficacy of TNKase may be further improved by enoxaparin substitution for unfractionated heparin, provided that enoxaparin dose adjustment is made for patients more than 75 years old. Hitherto, the small available randomized studies and international clinical registries suggest that pre-hospital TNKase is as effective as primary angioplasty, thus laying the foundations for a new fibrinolytic, TNKase-based strategy as the backbone of reperfusion in acute myocardial infarction.

Keywords: tenecteplase, TNKase, myocardial infarction, alteplase

Thrombolytic therapy versus primary angioplasty
Acute myocardial infarction presenting with ST-segment elevation (STEMI) is usually precipitated by plaque disruption with coronary thrombosis. The quick recanalization by either thrombolysis (TBL) or primary angioplasty (P-PCI) is the most important way to improve the short- and long-term prognosis. Current American and European guidelines “prefer” P-PCI, usually believed to achieve better coronary recanalization rates, prevent re-infarction and, ultimately, improve survival. However, many conceptual and practical items dispute this presumed superiority of P-PCI (Table 1).

The claim that P-PCI leads to a mortality reduction has never been shown in any single trial and is only suggested by an overview of 23 small trials, with only 2 trials enrolling more than 1000 patients. Furthermore, this small advantage is no longer significant when the comparison is made with the accelerated infusion of alteplase. Too many times have we observed the failure of such positive small meta-analyses, such as those evaluating the effects of nitrates or magnesium in acute myocardial infarction, or the efficacy of angiotensin-II blockers to prevent atrial fibrillation, or the efficacy of aspirin to prevent eclampsia.

The frequently quoted mortality reduction observed in patients treated with P-PCI in registries is largely biased both by the incapacity of statistical methods, such as the propensity score, to take into account important, intangible confounders, and by the entry in the P-PCI cohort of only those patients actually being treated and not those patients intended to treat.
regardless of whether TBL or P-PCI is used. It is now as possible in the first 3 hours from the onset of symptoms, most benefit may be achieved by treating as many patients 45 minutes. Since time is so important, it is believed that large myocardial infarction, for whom the equivalence of first medical contact, particularly among young patients with picture is dominated by time, with the small incremental benefit of P-PCI rapidly vanishing after 90 minutes after first medical contact, particularly among young patients with large myocardial infarction, for whom the equivalence of TBL and P-PCI may already be achieved by a delay of only 45 minutes. Since time is so important, it is believed that most benefit may be achieved by treating as many patients as possible in the first 3 hours from the onset of symptoms, regardless of whether TBL or P-PCI is used. It is now estimated that an efficient network can offer pre-hospital TBL in the first 3 hours in approximately 50% to 60% of STEMI patients.

TBL can be further improved by reducing the re-infarction rate by adjunctive use of clopidogrel and enoxaparin as soon as possible, ideally pre-hospital.

### Pharmacologic properties of TNKase in acute myocardial infarction

TNKase consists of the alteplase molecule (with the exception of three point mutations) and has a molecular weight of 65,000 kD. Thr substitution by Asn and the mutation of the sequence Lys–His–Arg–Arg to Ala–Ala–Ala–Ala prolong the half-life and increase the resistance to plasminogen activator inhibitor-1 (PAI-1). Additional substitution of Asn by Gln results in an 8-fold decrease in clearance and in a 200-fold increase in resistance to PAI-1.

Compared with other molecules used in clinical practice, TNKase has the highest degree of fibrin specificity and binding. Fibrin specificity, in turn, implies a reduced propensity for causing major non-cerebral bleeds, because lytic activity is restricted to plasmin on the fibrin surface, thus avoiding the breakdown of fibrinogen, factor V, factor VIII, and thrombomodulin. The TNKase conformational change reduces its elimination and prolongs its plasma half-life (α-half-life 11–20 minutes, β-half-life 41–138 minutes). Nitrates do not appear to affect TNKase levels, as opposed to what happens with alteplase levels. Moreover, the inhibition by PAI-1 is reduced 80 times compared with alteplase.

The above properties are interesting in the treatment of patients with STEMI, allowing single bolus infusion and preventing drug inactivation at the site of platelet-rich coronary thrombosis. In addition, TNKase has more intense anti-platelet properties both in vitro and in vivo compared with those of alteplase. In experimental models the thrombolytic potency of TNKase is 3-fold higher than that of alteplase.

### Clinical use of TNKase in acute myocardial infarction

The first experience of dose-testing TNKase in STEMI began in the TIMI-10A trial, showing a dose-dependent increase in TIMI-3 flow rates in the 5 to 50 mg dose range (p = 0.032).

In the dose-escalating pilot TIMI 10B patency trial, involving 886 patients 18 to 80 years old, bolus TNKase injection achieved coronary TIMI grade-3 flow rates of 55%, 63% and 66% at 90 minutes after 30, 40 and 50 mg bolus
The TIMI-3 flow rate was similar to that observed in the control group, receiving front-loaded alteplase.

The safety of TNKase in STEMI was investigated in ASSENT-1; 3235 patients received either 30 or 40 or 50 mg TNKase as a bolus injection. The total stroke rate at 30 days was 1.5% and the intracranial hemorrhage (ICH) rate was 0.8%, without significant differences between groups. Serious bleeding, requiring blood transfusion, occurred in 1.4% of patients in the TNKase group and in 7% of those treated with front-loaded alteplase. Importantly, TIMI-10B and ASSENT-1 showed the importance of reducing the heparin dose in conjunction with TNKase, to minimize the risk of ICH.

Survival data with TNKase have been tested in comparison with those achieved using front-loaded alteplase in the large, multicenter, confirmation ASSENT-2 trial. A total of 16,949 patients with STEMI in the first 6 hours from the onset of symptoms received either weight-adjusted TNKase over 5 to 10 seconds (less than 60 kg: 30 mg; 60–69.9 kg: 35 mg; 70–79.9 kg: 40 mg; 80–89.9 kg: 45 mg; and more than 90 kg: 50 mg) or front-loaded alteplase, along with aspirin and reduced-dose unfractionated heparin. This was an equivalence trial and all-cause mortality at 30 days was the primary end-point. There was no difference between TNKase and alteplase in mortality (6.18% vs 6.15%) and stroke rate, including ICH (0.93% vs 0.94%, respectively). Moreover, in the TNKase group there was a decreased rate in non-cerebral bleeds (26.43% vs 28.95%, p = 0.0003), in major bleeds (4.68% vs 5.94%, p = 0.0002) and in the need for blood transfusion (4.25% vs 5.49%, p = 0.0002) (Table 2). There was also a tendency for ICH to be decreased by TNKase among the high-risk population of females of more than 75 years old who weighed <67 kg (1.14% vs 3.02%). The general ASSENT-2 trial results were confirmed in all major subgroups, including those related to age, gender, infarct location, Killip class and diabetes status. Interestingly, mortality was significantly lower in the TNKase group when treatment was given more than 4 hours after the onset of symptoms (7.0% vs 9.2%, p = 0.018), a finding that could be attributed to the drug’s fibrin specificity leading to better dissolution of older coronary clots and confirms from a clinical standpoint the improved pharmacologic profile of this molecule.

Among other in-hospital outcomes, TNKase also reduced the rate of congestive heart failure (ie, Killip class >1: 6.1% vs 7.0%, p = 0.025).

Thus, the ASSENT-2 trial indicates that single-bolus TNKase is equivalent to the more complex accelerated alteplase infusion, in terms of mortality and mortality/stroke combination, with the further advantage of a decrease in major bleeding rate. These positive results were persisting after 1 year.

### TNKase and the adjutic use of antithrombotic therapy and of mechanical intervention

The possibility of further improving the effects of TNKase by means of new adjunctive treatments has been explored in ASSENT-3 and ENTIRE-TIMI 23 studies. In ASSENT-3 a total of 6095 patients with STEMI in the first 6 hours from the onset of symptoms were treated with either full-dose TNKase plus unfractionated heparin (UFH), full-dose TNKase plus enoxaparin (ENOX), or half-dose TNKase plus UFH and the GPIIB-IIIa inhibitor abciximab (ABX). Compared with UFH, the primary end-point (30-day mortality plus non-cerebral bleeds) was lower with ENOX (26.43% vs 28.95%, p = 0.0003), in major bleeds (4.68% vs 5.94%, p = 0.0002) and in the need for blood transfusion (4.25% vs 5.49%, p = 0.0002) (Table 2). There was also a tendency for ICH to be decreased by TNKase among the high-risk population of females of more than 75 years old who weighed <67 kg (1.14% vs 3.02%). The general ASSENT-2 trial results were confirmed in all major subgroups, including those related to age, gender, infarct location, Killip class and diabetes status. Interestingly, mortality was significantly lower in the TNKase group when treatment was given more than 4 hours after the onset of symptoms (7.0% vs 9.2%, p = 0.018), a finding that could be attributed to the drug’s fibrin specificity leading to better dissolution of older coronary clots and confirms from a clinical standpoint the improved pharmacologic profile of this molecule.

Among other in-hospital outcomes, TNKase also reduced the rate of congestive heart failure (ie, Killip class >1: 6.1% vs 7.0%, p = 0.025).

Thus, the ASSENT-2 trial indicates that single-bolus TNKase is equivalent to the more complex accelerated alteplase infusion, in terms of mortality and mortality/stroke combination, with the further advantage of a decrease in major bleeding rate. These positive results were persisting after 1 year.

### Table 2 Clinical studies with TNKase in STEMI

<table>
<thead>
<tr>
<th>Trial (year)</th>
<th>Patients</th>
<th>Comparison</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASSENT-2 (1999)</td>
<td>16,949</td>
<td>TNKase vs rt-PA</td>
<td>TNKase and rt-PA equivalent, ↓ major bleeding with TNKase</td>
</tr>
<tr>
<td>ASSENT-3 (2001)</td>
<td>6,095</td>
<td>ENOX vs ABX vs UFH &lt;sup&gt;a&lt;/sup&gt;</td>
<td>ENOX and ABX better than UFH</td>
</tr>
<tr>
<td>ENTIRE-TIMI 23 (2002)</td>
<td>483</td>
<td>ENOX vs ABX vs UFH &lt;sup&gt;a&lt;/sup&gt;</td>
<td>ENOX and ABX better than UFH, ↑ bleeding with ABX</td>
</tr>
<tr>
<td>ASSENT-3-PLUS (2003)</td>
<td>1,639</td>
<td>ENOX vs UFH &lt;sup&gt;b&lt;/sup&gt;, pre-hospital delivery</td>
<td>↓ reinfarction with ENOX, ↑ stroke/intracranial bleed</td>
</tr>
<tr>
<td>CAPITAL-AMI (2005)</td>
<td>170</td>
<td>F-PCI &lt;sup&gt;c&lt;/sup&gt; vs TNKase &lt;sup&gt;e&lt;/sup&gt;</td>
<td>↓ residual ischemia with F-PCI</td>
</tr>
<tr>
<td>ASSENT-4 (2006)</td>
<td>1,667</td>
<td>F-PCI &lt;sup&gt;c&lt;/sup&gt; vs P-PCI &lt;sup&gt;f&lt;/sup&gt;</td>
<td>↑ death/ischemia/bleeding in the F-PCI group</td>
</tr>
<tr>
<td>WEST (2006)</td>
<td>304</td>
<td>TNKase vs F-PCI &lt;sup&gt;c&lt;/sup&gt; vs P-PCI</td>
<td>TNKase and F-PCI comparable to P-PCI</td>
</tr>
<tr>
<td>GRACIA-2 (2007)</td>
<td>212</td>
<td>TNKase &lt;sup&gt;e&lt;/sup&gt; vs P-PCI</td>
<td>↑ reperfusion with TNKase &lt;sup&gt;e&lt;/sup&gt; Similar ventricular damage</td>
</tr>
</tbody>
</table>

<sup>a</sup>All patients in the trial received TNKase.

<sup>b</sup>P-PCI: Primary angioplasty.

<sup>c</sup>F-PCI: Primary angioplasty, facilitated by TNKase.

<sup>d</sup>TNKase followed by routine angioplasty within 3–12 hours ("pharmaco-invasive" approach).
in-hospital reinfarction and in-hospital refractory ischemia) was reduced by ENOX (11.4% vs 15.4%, p = 0.0002) and by the combination of UFH plus ABX (11.1%, p = 0.0001). When in-hospital ICH or major bleeds were added to the primary end-point (so called efficacy plus safety end-point), again, a significant reduction was observed both in the ENOX group (13.7% vs 17.0%, p = 0.0037) and in the UFH plus ABX group (14.2%, p = 0.01416). ABX increased the rate of thrombocytopenia compared to both ENOX and UFH (3.2% vs 1.2% and 1.3% respectively, p = 0.0001) and it also increased the cost of treatment.29

Similar results were observed in the smaller ENTIRE-TIMI 23 trial.28 This trial had a design very similar to that of ASSENT-3, although there was a further group receiving ENOX in combination with ABX and half-dose TNKase. Overall, the adjunctive use of ENOX with TNKase, compared with UFH, reduced the combined incidence of death/myocardial infarction at 30 days (4.4% vs 15.9%, p = 0.005). ABX did not further decrease the end-point; rather, ABX increased the risk of major bleeding (5.2% vs 2.4% compared with UFH alone and 8.5% vs 1.9% compared with ENOX alone). Major bleeding was also increased when half-dose TNKase was combined with epifibatide, a small-molecule GP IIb-IIIa inhibitor in the INTEGRITI study.30 In conjunction with the GUSTO-V data,31 ASSENT-3, ENTIRE-TIMI-23 and INTEGRITI indicate that GPIIb-IIIa agents should not be associated with thrombolytic drugs.

In conclusion, ASSENT-3 and ENTIRE-TIMI 23 showed that a much simpler thrombolytic regimen is feasible, permitting bolus administration of both TNKase and of adjunctive low-molecular-weight heparin.

This new regimen was tested in the pre-hospital phase of STEMI treatment in the ASSENT-3-PLUS study.32 In this trial, after electrocardiographic confirmation was obtained in the field, 1639 patients were treated with TNKase and randomly allocated to ENOX or UFH adjunctive treatment. Of interest, 53% of patients could be treated in the first 2 hours, a much higher proportion compared with that observed in previous studies. In the pre-hospital setting ENOX tended to reduce the composite of 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia (14.2% vs 17.4%, p = 0.08), but there was no difference in the efficacy plus safety end-point, also including the rate of ICH or major bleeding (18.3% vs 20.3%, p = NS). ENOX reduced the reinfarction rate (3.5% vs 5.8%, p = 0.028), but increased the rate of total stroke (2.9% vs 1.3%, p = 0.026) and of ICH (2.20% vs 0.97%, p = 0.047). The increase in ICH occurred in the group of patients more than 75 years old. A pre-specified pooled analysis of data from ASSENT-3 and ASSENT-3-PLUS trials largely confirmed the utility of using ENOX instead of UFH in conjunction with TNKase, reducing the primary efficacy end-point (composite of death, reinfarction and refractory ischemia) from 16.0% to 12.2%, p < 0.001 and the primary efficacy plus safety (ICH or major bleeding) end-point from 18.0% to 15.0%, p = 0.003.33

Among the 1049 patients who required urgent revascularization the ENOX beneficial effect was even larger (15.4% vs 10.1%, p = 0.013). The excess in stroke rates observed with ENOX (1.3% vs 0.9%), although not significant, was mainly due to an excess in ICH among women of more than 75 years old in ASSENT-3-PLUS.

Following these observations, the intravenous bolus of ENOX was omitted and the maintenance dose was reduced by 25% in patients of more than 75 years old in the large definitive confirmation EXTRACT-TIMI 25 trial.15

The role of the routine, immediate use of coronary angioplasty (so called “facilitated” angioplasty, F-PCI) after treatment with TNKase was first explored in CAPITAL-AMI.34 This was a small study randomizing 170 high-risk STEMI patients treated with TNKase toward immediate revascularization by PCI or to conservative management. The primary end-point was the composite of death, reinfarction, recurrent unstable ischemia, or stroke at 6 months. The median time from the onset of symptoms to TNKase administration was 120 minutes and the median time from symptoms to balloon inflation 204 minutes. Overall, the primary end-point was reduced by immediate PCI from 24.4% to 11.6% (p = 0.04), a result driven mainly by the reduction in the rate of recurrent unstable ischemia (p = 0.03). There were no differences in death, reinfarction, stroke or major bleeding.

These encouraging results stimulated the planning of the larger ASSENT-4 PCI trial,35 a trial designed to investigate whether TNKase facilitation would improve the prognosis of patients for whom a time-delay of 1 to 3 hours before P-PCI was anticipated. The trial design was open-label and the primary end-point was the composite of death or congestive heart failure or shock within 90 days. Only 1667 of the originally planned 4000 patients were enrolled, because the trial was prematurely interrupted by the data and safety monitoring board for an excess of in-hospital mortality in the group where P-PCI was facilitated by TNKase (6% vs 3%, p = 0.0105). The median time from TNKase injection to first balloon inflation was 104 minutes. A TIMI-3 flow was achieved before P-PCI in 43% of TNKase-treated patients and in 15% of patients in the control group (p < 0.0001).
The primary end-point at 90 days was increased in the facilitated group (19% vs 13%, \( p = 0.0045 \)), along with the stroke rate (1.8% vs 0%, \( p < 0.0001 \)). These disappointing results have been attributed, in retrospect, to an alleged pro-thrombotic effect of TBL and, more convincingly, to the risk of creating an intra-plaque hemorrhage by inflating the balloon in the first 2 hours after TBL (ie, in a lytic state). In retrospect, the risk of death at 90 days was reduced by TNKase facilitation when patients were randomized in ambulance (relative risk 0.74, 95% CI 0.24–2.30) and mostly increased when patients were recruited in P-PCI capable hospitals (relative risk 1.62, 95% CI 0.94–2.81). These observation raise important methodological issues about ASSENT-4 PCI, since 45% patients were actually enrolled in P-PCI capable hospital, a design not exactly germane as to define what is the best strategy for the treatment of patients at the earliest point of care, particularly in the pre-hospital setting. This holds true particularly when considering that the trial was open-label.

More pertinent to investigating the role of TNKase facilitation is the WEST study, a randomized, open-label, feasibility study of 304 STEMI patients enrolled in the community (40% enrolled pre-hospital). All patients received aspirin and ENOX and were randomized to either TNKase, or to TNKase followed by PCI within 24 hours (including rescue PCI for reperfusion failure) or to P-PCI. The time from the onset of symptoms to randomization was 113, 130 and 176 minutes respectively. There were no differences between the three groups in the primary composite of death or reinfarction, refractory ischemia, congestive heart failure, cardiogenic shock or major ventricular arrhythmia (25% vs 24% vs 23%, \( p = \text{NS} \)). In the group receiving plain TNKase there was a higher rate of the death/reinfarction combination (13.0% vs 6.7% vs 4.0%, \( p = 0.021 \)), but not of death (4.0% vs 1.0% vs 1.0%, \( p = \text{NS} \)).

Thus, the WEST trial confirms the data from CAPTIM when delivered very rapidly, possibly in the pre-hospital phase, TNKase is very competitive with P-PCI and may offer a very simple and effective treatment, particularly if subsequent PCI is offered to those patients with recurrent ischemia or deemed at high clinical risk.

TNKase followed by early routine PCI (within 3–12 hours, so called “pharmaco-invasive” approach) has been compared with P-PCI in 212 patients enrolled in the GRACIA-2 study. This is a non-inferiority trial designed to evaluate whether a lytic strategy represents a reasonable option for STEMI patients, irrespective of geographic or logistic barriers, when compared with P-PCI. The primary end-points were epicardial and myocardial reperfusion and the extent of left ventricular damage (as assessed by infarct size and left ventricular function). Complete ST-segment resolution at the electrocardiogram was observed more frequently in the TNKase group (61% vs 43%, \( p = 0.01 \)), implying an improved myocardial perfusion (as measured by the TIMI myocardial perfusion grade at 60 minutes).38 Infarct size and left ventricular ejection fraction were similar in the two groups (Figure 1).

It may be concluded that the results of the WEST study are confirmed by GRACIA-2, suggesting the comparable efficacy of TNKase (with rescue/routine PCI) and P-PCI.

Most relevant to pathophysiology and clinical practice, is the finding of GRACIA-2 (in combination with ASSENT-4 PCI)
that routine PCI after TNKase should be postponed at least 3 to 12 hours to achieve the benefit.

Conclusions

TNKase treatment of patients with STEMI is truly evidence-based.

More than 27,000 patients have been enrolled in several trials, by different investigators across the world, and addressing all major issues: strategy of reperfusion, comparison with other thrombolytic agents, choice of the best adjunctive anti-thrombotic treatment, and optimal patient management after drug injection.

For all the above considerations the American College of Chest Physicians (ACCP) recognizes TNKase as a Class 1A recommendation in the treatment of STEMI patients within 12 hours from the onset of symptoms.

There are indeed several reasons for choosing TNKase (Table 3): the easy way it may be used in ambulance (this use is also a Class IA ACCP recommendation), the high thrombolytic potency with a decreased risk of inducing major bleeds, and the really competitive results that may be expected for that majority of patients presenting in the first 3 hours, compared with P-PCI.

Indeed, TNKase is now embraced in many pre-hospital thrombolytic reperfusion protocols, such as the Vienna STEMI Registry, The Mayo Clinic STEMI Protocol, and The French FAST-MI registry.

Therefore, a modern, TNKase-based “fibrinolytic strategy” is now offered to the health care system, which may overcome the huge logistic problems connected with the utopian, universal P-PCI implementation.

Pre-hospital TNKase is a real opportunity to offer timely reperfusion to as many patients as possible in an easy way, an opportunity that the health care system cannot miss.

Table 4 summarizes how TNKase is used in clinical practice.

### Table 3 Reasons for using TNKase in STEMI patients

<table>
<thead>
<tr>
<th>Reason</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNKase is the most fibrin-specific thrombolytic agent available</td>
<td></td>
</tr>
<tr>
<td>TNKase may be injected by single intravenous bolus in 5–10 seconds</td>
<td></td>
</tr>
<tr>
<td>TNKase is as effective as accelerated rt-PA, but with less major bleeding</td>
<td></td>
</tr>
<tr>
<td>Pre-hospital TNKase (with rescue/routine PCI) seems as effective as primary angioplasty</td>
<td></td>
</tr>
</tbody>
</table>

### Table 4 How to use TNKase in STEMI patients

<table>
<thead>
<tr>
<th>Bolus intravenous injection of TNKase over 5–10 seconds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TNKase dose according to body weight (BW)</strong></td>
</tr>
<tr>
<td>30 mg if BW &lt; 60.0 kg</td>
</tr>
<tr>
<td>35 mg if BW between 60.0 and 69.9 kg</td>
</tr>
<tr>
<td>40 mg if BW between 70.0 and 79.9 kg</td>
</tr>
<tr>
<td>45 mg if BW between 80.0 and 89.9 kg</td>
</tr>
<tr>
<td>50 mg if BW ≥ 90.0 kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjunctive anti-platelet therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin: 160–325 mg, followed by 75–162 mg per day, indefinitely</td>
</tr>
<tr>
<td>Clopidogrel: 75 mg per day (for at least 28 days if no stenting, 1 month if using a bare metal stent, 1 year if using a drug eluting stent)</td>
</tr>
<tr>
<td>Initial clopidogrel dose: 300 mg if age ≥ 75 or if a stent is implanted</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjunctive unfractionated heparin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous bolus: 60 U per kg (maximum 4000 U)</td>
</tr>
<tr>
<td>Intravenous infusion: 12 U per kg per hour (maximum 1000 U per hour)</td>
</tr>
<tr>
<td>Target activated partial thromboplastin time: 1.5–2.0 control</td>
</tr>
<tr>
<td>Treatment duration: minimum 48 hours</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adjunctive enoxaparin (only if serum creatinine &lt; 2.5 mg/dL in men, &lt; 2.0 in women):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 75 years old: Intravenous bolus of 30 mg</td>
</tr>
<tr>
<td>Less than 75 years old: Subcutaneous injection of 1 mg/kg every 12 hours</td>
</tr>
<tr>
<td>At least 75 years old: No intravenous bolus</td>
</tr>
<tr>
<td>At least 75 years old: Subcutaneous injection of 0.75 mg/kg every 12 hours</td>
</tr>
<tr>
<td>If the creatinine clearance is &lt; 3.0 mg/dL: subcutaneous injection every 24 hours</td>
</tr>
<tr>
<td>Treatment duration: for the duration of index hospitalization, up to 8 days</td>
</tr>
</tbody>
</table>

For patients undergoing PCI after TNKase

- If on unfractionated heparin: additional boluses as needed
- If on enoxaparin: no further anticoagulant if < 8 hours from the subcutaneous injection
- If on enoxaparin: additional intravenous bolus of 0.3 mg/kg if 8–12 hours after the subcutaneous injection
Disclosures
The authors have no conflicts of interest to disclose.

References


